News

Article

In the Lab eNewsletter

Pharmaceutical Technology's In the Lab eNewsletter, December 2022
Volume17
Issue 12

Salipro Biotech Enters into Collaboration with Sanofi

Salipro Biotech has entered into a collaboration and license agreement with Sanofi to advance discovery programs.

Salipro Biotech announced on Nov. 8, 2022 that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.

The collaboration will combine Salipro Biotech’s expertise and its Salipro platform technology to develop stable antigens of GPCRs, ion channels, and transporters with Sanofi’s drug discovery programs to move forward the generation of biologics.

“We are excited to work closely with the innovative team at Sanofi to accelerate their drug discovery efforts against a selected membrane protein drug target,” said Jens Frauenfeld, CEO of Salipro Biotech, in a press release. “Combining our expertise and platform technology to generate Salipro-stabilized drug targets with Sanofi’s expertise in biologics discovery and development will open up entirely new possibilities to make the undruggable druggable for Sanofi’s biopharmaceutical pipeline.”

Source: Salipro Biotech

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content